Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

356 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Encorafenib plus cetuximab treatment in BRAF V600E-mutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case series.
Hafliger E, Boccaccino A, Lapeyre-Prost A, Perret A, Gallois C, Antista M, Pilla L, Lecomte T, Scartozzi M, Soularue E, Salvatore L, Bourgeois V, Salati M, Tougeron D, Evesque L, Vaillant JN, El-Khoury R, Lonardi S, Cremolini C, Taieb J. Hafliger E, et al. Among authors: scartozzi m. Eur J Cancer. 2022 Jun;168:34-40. doi: 10.1016/j.ejca.2022.03.011. Epub 2022 Apr 15. Eur J Cancer. 2022. PMID: 35436675
A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation.
Cascinu S, Berardi R, Salvagni S, Beretta GD, Catalano V, Pucci F, Sobrero A, Tagliaferri P, Labianca R, Scartozzi M, Crocicchio F, Mari E, Ardizzoni A. Cascinu S, et al. Among authors: scartozzi m. Br J Cancer. 2008 Jan 15;98(1):71-6. doi: 10.1038/sj.bjc.6604121. Epub 2007 Dec 4. Br J Cancer. 2008. PMID: 18059397 Free PMC article. Clinical Trial.
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.
Loupakis F, Pollina L, Stasi I, Ruzzo A, Scartozzi M, Santini D, Masi G, Graziano F, Cremolini C, Rulli E, Canestrari E, Funel N, Schiavon G, Petrini I, Magnani M, Tonini G, Campani D, Floriani I, Cascinu S, Falcone A. Loupakis F, et al. Among authors: scartozzi m. J Clin Oncol. 2009 Jun 1;27(16):2622-9. doi: 10.1200/JCO.2008.20.2796. Epub 2009 Apr 27. J Clin Oncol. 2009. PMID: 19398573
Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan.
Scartozzi M, Mandolesi A, Giampieri R, Pierantoni C, Loupakis F, Zaniboni A, Galizia E, Giustini L, Silva RR, Bisonni R, Berardi R, Biagetti S, Menzo S, Falcone A, Bearzi I, Cascinu S. Scartozzi M, et al. Int J Cancer. 2010 Oct 15;127(8):1941-7. doi: 10.1002/ijc.25193. Int J Cancer. 2010. PMID: 20099280 Free article.
Pharmacogenomics of cetuximab in metastatic colorectal carcinoma.
Silvestris N, Vincenzi B, Brunetti AE, Loupakis F, Dell'Aquila E, Russo A, Scartozzi M, Giampieri R, Cascinu S, Lorusso V, Tonini G, Falcone A, Santini D. Silvestris N, et al. Among authors: scartozzi m. Pharmacogenomics. 2014 Sep;15(13):1701-15. doi: 10.2217/pgs.14.124. Pharmacogenomics. 2014. PMID: 25410895 Review.
Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients.
Giampieri R, Salvatore L, Del Prete M, Prochilo T, D'Anzeo M, Loretelli C, Loupakis F, Aprile G, Maccaroni E, Andrikou K, Bianconi M, Bittoni A, Faloppi L, Demurtas L, Montironi R, Scarpelli M, Falcone A, Zaniboni A, Scartozzi M, Cascinu S. Giampieri R, et al. Among authors: scartozzi m. Sci Rep. 2016 Apr 27;6:25195. doi: 10.1038/srep25195. Sci Rep. 2016. PMID: 27117754 Free PMC article.
356 results